Literature DB >> 35060411

Minnesota Electronic Health Record Consortium COVID-19 Project: Informing Pandemic Response Through Statewide Collaboration Using Observational Data.

Tyler N A Winkelman1,2, Karen L Margolis3, Stephen Waring4, Peter J Bodurtha2, Rohan Khazanchi2,5,6, Stefan Gildemeister7, Pamela J Mink7, Malini DeSilva3, Anne M Murray8,9, Nayanjot Rai10, Julie Sonier11, Claire Neely12, Steven G Johnson13, Alanna M Chamberlain14, Yue Yu14, Lynn M McFarling15, R Adams Dudley13,16,17, Paul E Drawz10.   

Abstract

OBJECTIVE: Robust disease and syndromic surveillance tools are underdeveloped in the United States, as evidenced by limitations and heterogeneity in sociodemographic data collection throughout the COVID-19 pandemic. To monitor the COVID-19 pandemic in Minnesota, we developed a federated data network in March 2020 using electronic health record (EHR) data from 8 multispecialty health systems.
MATERIALS AND METHODS: In this serial cross-sectional study, we examined patients of all ages who received a COVID-19 polymerase chain reaction test, had symptoms of a viral illness, or received an influenza test from January 3, 2016, through November 7, 2020. We evaluated COVID-19 testing rates among patients with symptoms of viral illness and percentage positivity among all patients tested, in aggregate and by zip code. We stratified results by patient and area-level characteristics.
RESULTS: Cumulative COVID-19 positivity rates were similar for people aged 12-64 years (range, 15.1%-17.6%) but lower for adults aged ≥65 years (range, 9.3%-10.7%). We found notable racial and ethnic disparities in positivity rates early in the pandemic, whereas COVID-19 positivity was similarly elevated across most racial and ethnic groups by the end of 2020. Positivity rates remained substantially higher among Hispanic patients compared with other racial and ethnic groups throughout the study period. We found similar trends across area-level income and rurality, with disparities early in the pandemic converging over time. PRACTICE IMPLICATIONS: We rapidly developed a distributed data network across Minnesota to monitor the COVID-19 pandemic. Our findings highlight the utility of using EHR data to monitor the current pandemic as well as future public health priorities. Building partnerships with public health agencies can help ensure data streams are flexible and tailored to meet the changing needs of decision makers.

Entities:  

Keywords:  COVID-19; health disparities; health informatics; infectious diseases; public health surveillance

Mesh:

Year:  2022        PMID: 35060411      PMCID: PMC8900228          DOI: 10.1177/00333549211061317

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  13 in total

Review 1.  Uses of electronic health records for public health surveillance to advance public health.

Authors:  Guthrie S Birkhead; Michael Klompas; Nirav R Shah
Journal:  Annu Rev Public Health       Date:  2015-01-02       Impact factor: 21.981

2.  Electronic health record-based disease surveillance systems: A systematic literature review on challenges and solutions.

Authors:  Ali Aliabadi; Abbas Sheikhtaheri; Hossein Ansari
Journal:  J Am Med Inform Assoc       Date:  2020-12-09       Impact factor: 4.497

3.  International statistical classification of diseases and related health problems. Tenth revision.

Authors:  G R Brämer
Journal:  World Health Stat Q       Date:  1988

4.  Racism, Not Race, Drives Inequity Across the COVID-19 Continuum.

Authors:  Rohan Khazanchi; Charlesnika T Evans; Jasmine R Marcelin
Journal:  JAMA Netw Open       Date:  2020-09-01

5.  Putting the Public Back in Public Health - Surveying Symptoms of Covid-19.

Authors:  Andrew T Chan; John S Brownstein
Journal:  N Engl J Med       Date:  2020-06-05       Impact factor: 91.245

6.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

7.  Canada's Pandemic Influenza Preparedness: Surveillance strategy.

Authors:  B Henry
Journal:  Can Commun Dis Rep       Date:  2018-01-04

8.  The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries.

Authors:  Michael C Grant; Luke Geoghegan; Marc Arbyn; Zakaria Mohammed; Luke McGuinness; Emily L Clarke; Ryckie G Wade
Journal:  PLoS One       Date:  2020-06-23       Impact factor: 3.240

9.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

10.  Characteristics of COVID-19 infection in Beijing.

Authors:  Sijia Tian; Nan Hu; Jing Lou; Kun Chen; Xuqin Kang; Zhenjun Xiang; Hui Chen; Dali Wang; Ning Liu; Dong Liu; Gang Chen; Yongliang Zhang; Dou Li; Jianren Li; Huixin Lian; Shengmei Niu; Luxi Zhang; Jinjun Zhang
Journal:  J Infect       Date:  2020-02-27       Impact factor: 6.072

View more
  1 in total

1.  Trends in COVID-19 Vaccine Administration and Effectiveness Through October 2021.

Authors:  Tyler N A Winkelman; Nayanjot K Rai; Peter J Bodurtha; Alanna M Chamberlain; Malini DeSilva; Jessica Jeruzal; Steven G Johnson; Anupam Kharbanda; Niall Klyn; Pamela J Mink; Miriam Muscoplat; Stephen Waring; Yue Yu; Paul E Drawz
Journal:  JAMA Netw Open       Date:  2022-03-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.